Pilot study evaluated safety and vision effects of subconjunctival sirolimus injections in bilateral geographic atrophy
This pilot study tested whether sirolimus, injected under the outer layer of the eye, was safe and could preserve vision in patients with bilateral geographic atrophy (advanced dry AMD). Participants with visual acuity between 20/20 and 20/400 received sirolimus injections every 3 months over 2 to 3 years, with regular eye examinations, imaging, and blood tests to monitor safety and vision outcomes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 14, 2020 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- 36 months
- Population
- People with geographic atrophy (GA) in both eyes with visual acuity between 20/20 and 20/400 in each eye; women of childbearing potential are eligible (implied by pregnancy testing)
- Primary outcome
- Safety of subconjunctival sirolimus and vision preservation in patients with bilateral geographic atrophy
- Effect size
- —
- Significance
- Not reported
- Journal
- National Eye Institute (NEI)
- Published
- Jul 14, 2020
Sources
Primary source
- National Eye Institute (NEI) ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.